thalidomide has been researched along with Endothelioma, Vascular in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, a well-known immunomodulatory compound, has an anti-angiogenic activity, which may be utilized for the treatment of angiogenesis-related diseases such as hemangioendothelioma." | 7.91 | Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma. ( Guo, L; Liu, H; Liu, L; Ren, L; Song, N; Wan, Z; Xu, B, 2019) |
| "Thalidomide, a well-known immunomodulatory compound, has an anti-angiogenic activity, which may be utilized for the treatment of angiogenesis-related diseases such as hemangioendothelioma." | 3.91 | Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma. ( Guo, L; Liu, H; Liu, L; Ren, L; Song, N; Wan, Z; Xu, B, 2019) |
| " Subsequent investigations resulted in the diagnosis of type I cryoglobulinemia; the lesions resolved completely following treatment of the underlying disorder with lenalidomide." | 3.79 | Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner. ( Boyapati, A; Khan, S; Mar, A; Sheridan, A, 2013) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor of childhood that is locally aggressive but has little metastatic potential and by itself is not known to be lethal." | 1.35 | Kaposiform hemangioendothelioma in multiple spinal levels without skin changes. ( Bradeen, HA; Kalof, AN; Lisle, JW, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, L | 1 |
| Wan, Z | 1 |
| Xu, B | 1 |
| Ren, L | 1 |
| Liu, H | 1 |
| Song, N | 1 |
| Liu, L | 1 |
| Boyapati, A | 1 |
| Khan, S | 1 |
| Mar, A | 1 |
| Sheridan, A | 1 |
| Lisle, JW | 1 |
| Bradeen, HA | 1 |
| Kalof, AN | 1 |
3 other studies available for thalidomide and Endothelioma, Vascular
| Article | Year |
|---|---|
Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Movement; Hemangioendothelioma; Humans; Mice; Ribonu | 2019 |
Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner.
Topics: Aged; Angiogenesis Inhibitors; Cryoglobulinemia; Hemangioendothelioma; Humans; Lenalidomide; Male; R | 2013 |
Kaposiform hemangioendothelioma in multiple spinal levels without skin changes.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Celecoxib; Chil | 2009 |